This presentation focuses on the changes most likely to affect dermatology practice now: adjuvant therapy after definitive local treatment, emerging response-guided strategies designed to reshape subsequent surgery or radiation, and the movement of immunotherapy into earlier disease.
Three themes
01
Adjuvant therapy becomes real
C-POST establishes a postoperative role for cemiplimab in a selected, very-high-risk CSCC population.
02
Response starts to guide care
De-Squamate, MATISSE, and FIRST move beyond measuring response toward adapting subsequent local treatment.
03
Immunotherapy moves earlier
CLEAR-CSCC and related studies test whether systemic or intralesional immunotherapy can challenge surgery as the automatic first step for selected disease.
View the presentationOpen the web-based Reveal.js slide deck.
Launch slides →
Presented as part of Skin Cancer Forum Part I at the 27th Annual Las Vegas Dermatology Seminar, Bellagio, Las Vegas. Conference agenda.
This site represents our opinions only. See our full
Disclaimer and
Terms of Use Agreement.